期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells 被引量:26
1
作者 Juan Zhang~1 Jin-Kun Zhang~2 Shao-Hong Zhuo~3 Hai-Bin Chen~2 1 Clinical Laboratory,The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,Guangdong Province,China2 Cancer Pathology Laboratory,Shantou University Medical College,Shantou 515031,Guangdong Province,China3 Department of Gastroenterology,Third Municipal Hospital of Shantou,Shantou 515073,Guangdong Province,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第5期690-694,共5页
AIM: To prepare a cancer vaccine (H(22)-DC) expressing high levels of costimulatory molecules based on fusions of hepatocarcinoma cells (H(22)) with dendritic cells (DC) of mice and to analyze the biological character... AIM: To prepare a cancer vaccine (H(22)-DC) expressing high levels of costimulatory molecules based on fusions of hepatocarcinoma cells (H(22)) with dendritic cells (DC) of mice and to analyze the biological characteristics and induction of specific CTL activity of H(22)-DC. METHODS: DCs were isolated from murine spleen by metrizamide density gradient centrifugation, purified based on its characteristics of semi-adhesion to culture plates and FcR-,and were cultured in the medium containing GM-CSF and IL-4. A large number of DC were harvested. DCs were then fused with H(22) cells by PEG and the fusion cells were marked with CD11c MicroBeads. The H(22)-DC was sorted with Mimi MACS sorter. The techniques of cell culture, immunocytochemistry and light microscopy were also used to test the characteristics of growth and morphology of H(22)-DC in vitro. As the immunogen, H(22)-DC was inoculated subcutaneously into the right armpit of BALB/C mice, and their tumorigenicity in vivo was observed. MTT was used to test the CTL activity of murine spleen in vivo. RESULTS: DC cells isolated and generated were CD11c+ cells with irregular shape, and highly expressed CD80, CD86 and CD54 molecules. H22 cells were CD11c- cells with spherical shape and bigger volume, and did not express CD80, CD86 and CD54 molecules.H(22)-DC was CD11c+ cells with bigger volume, being spherical, flat or irregular in shape, and highly expressed CD80, CD86 and CD54 molecules, too. H(22)-DC was able to divide and proliferate in vitro, but its activity of proliferation was significantly decreased as compared with H(22) cells and its growth curve was flatter than H(22) cells. After subcutaneous inoculation over 60 days, H(22)-DC showed no tumorigenecity in mice, which was significantly different from control groups (P【0.01). The spleen CTL activity against H(22) cells in mice implanted with fresh H(22)-DC was significantly higher than control groups (P 【 0.01). CONCLUSION: H(22)-DC could significantly stimulate the specific CTL activity of murine spleen, which suggests that the fusion cells have already obtained the function of antigen presenting of parental DC and could present H(22)specific antigen which has not been identified yet, and H(22)-DC could induce antitumor immune response; although simply mixed H(22) cells with DC could stimulate the specific CTL activity which could inhibit the growth of tumor in some degree, it could not prevent the generation of tumor. It shows that the DC vaccine is likely to become a helpful approach in immunotherapy of hepatocarcinoma. 展开更多
关键词 cancer Vaccines Animals Antigens CD Antigens CD80 Antigens CD86 Cell Fusion Dendritic Cells Integrin alphaXbeta2 Intercellular Adhesion Molecule-1 liver Neoplasms Experimental control Male Membrane Glycoproteins MICE Mice Inbred BALB C Research support Non-U.s. Gov't spleen
下载PDF
解氏肝癌2号方对肝癌H22荷瘤小鼠作用的研究 被引量:2
2
作者 崔佳 朱成功 +1 位作者 赵莹莹 解建国 《现代中西医结合杂志》 CAS 2014年第33期3655-3657,3661,共4页
目的研究解氏肝癌2号方对肝癌H22荷瘤小鼠的抗肿瘤及免疫调节作用。方法建立H22肝癌小鼠模型,随机分为模型组、解氏肝癌2号方组、中药半枝莲组和白细胞介素-2(IL-2)组共4组,每组10只,并予第2天始给予相应药物灌胃。第15天处死小鼠,取出... 目的研究解氏肝癌2号方对肝癌H22荷瘤小鼠的抗肿瘤及免疫调节作用。方法建立H22肝癌小鼠模型,随机分为模型组、解氏肝癌2号方组、中药半枝莲组和白细胞介素-2(IL-2)组共4组,每组10只,并予第2天始给予相应药物灌胃。第15天处死小鼠,取出肿瘤,称取瘤质量,计算抑瘤率、胸腺指数、脾指数等指标,并通过免疫组化的方法检测凋亡相关蛋白Bcl-2和Bax的表达情况。结果 1解氏肝癌2号方组与IL-2组体质量增加更为明显。2解氏肝癌2号方组的抑瘤率与中药半枝莲组相仿,二者均显著高于IL-2组。3解氏肝癌2号方组与IL-2组的胸腺指数和脾脏指数无明显差异,均明显高于中药半枝莲组及模型组。4解氏肝癌2号方组Bcl-2水平与中药半枝莲组相仿,低于模型组和IL-2组,模型组最高;而Bax水平正好相反,解氏肝癌2号方组与中药半枝莲组均高于模型组和IL-2组,模型组最低。结论解氏肝癌2号方能明显改善小鼠的一般生活状态,增加小鼠体质量,对肿瘤有明显抑制作用,并且下调肝癌H22荷瘤小鼠的凋亡相关蛋白Bcl-2的表达,上调Bax的表达,能够明显改善机体免疫功能,减轻恶性肿瘤对机体的损害,减轻病痛,使人体与癌肿长期共存,互不侵犯。本实验为临床"带瘤生存"理念提供了坚实的理论基础。 展开更多
关键词 原发性肝癌 解氏肝癌2号方 H22细胞株 BCL-2 BAX
下载PDF
中药方剂对合并原发性肝癌的2型糖尿病患者血糖和免疫水平影响观察 被引量:7
3
作者 周宁 冀锐 +3 位作者 张永静 张萱 李迎泽 王虎明 《中国药师》 CAS 2019年第7期1275-1277,共3页
目的:观察中药方剂治疗对合并原发性肝癌的2型糖尿病患者的血糖及免疫水平的影响。方法:合并原发性肝癌的2型糖尿病患者72例根据自愿选择治疗方法,分为对照组32例和观察组40例。两组患者首先接受肝动脉化疗栓塞(TACE)联合肝动脉灌注奥... 目的:观察中药方剂治疗对合并原发性肝癌的2型糖尿病患者的血糖及免疫水平的影响。方法:合并原发性肝癌的2型糖尿病患者72例根据自愿选择治疗方法,分为对照组32例和观察组40例。两组患者首先接受肝动脉化疗栓塞(TACE)联合肝动脉灌注奥沙利铂(OXA)。在此基础上,对照组予二甲双胍,观察组给予益气养阴活血中药方剂治疗。比较两组患者治疗前后空腹和餐后血糖、糖化血红蛋白水平,以及CD3^+、CD4^+、CD4^+/CD8^+水平变化。结果:治疗后两组患者的空腹血糖、餐后血糖和糖化血红蛋白水平均较前明显降低(P<0.05),且观察组各项血糖指标均优于对照组(P<0.05)。对照组治疗前后T淋巴细胞亚群水平无明显变化(P>0.05),而观察组CD3^+、CD4^+、CD4^+/CD8^+均较前明显提高(P<0.05)。结论:中药方剂治疗合并原发性肝癌的2型糖尿病患者,不仅可以有效降低血糖,还可以提高患者的免疫水平。 展开更多
关键词 中药方剂 2型糖尿病 原发性肝癌 血糖 免疫水平
下载PDF
谢晶日教授运用药对治疗巴雷特食管经验 被引量:1
4
作者 周曌莹 单葳葳 +1 位作者 房子铭 谢晶日 《世界中医药》 CAS 2023年第12期1715-1718,共4页
谢晶日教授临床经验丰富,对巴雷特食管(BE)的治疗见解独特,通过临床医案收集、汇总与分析再结合谢晶日教授的临证配伍用药规律得出以下5组常用药对,包括海螵蛸与煅瓦楞子、藿香与佩兰、当归与川芎、焦三仙与鸡内金、三七与白及。药对配... 谢晶日教授临床经验丰富,对巴雷特食管(BE)的治疗见解独特,通过临床医案收集、汇总与分析再结合谢晶日教授的临证配伍用药规律得出以下5组常用药对,包括海螵蛸与煅瓦楞子、藿香与佩兰、当归与川芎、焦三仙与鸡内金、三七与白及。药对配伍精细,具有实用、便捷和灵活的特点,因此具有极高的临床价值。现将结合谢晶日教授“肝脾论”思想,从四气五味,药物性味归经,名医经典、现代药理研究等多方面对谢晶日教授运用药对治疗BE经验进行探析。 展开更多
关键词 食管癌 巴雷特食管 胃食管反流病 对药 @谢晶日 肿瘤 中药 肝脾论
下载PDF
人参皂苷结构修饰物HRG的体内抗肿瘤活性研究 被引量:4
5
作者 赵凤丽 袁野 +4 位作者 孙婷婷 朱雷 黄樱 刘墨祥 李吉萍 《中国药学杂志》 CAS CSCD 北大核心 2012年第20期1625-1629,共5页
目的探讨新化合物3β,12β,20(S)-三羟基达玛-3-O-β-D-吡喃葡萄糖基(1-2)-β-D-吡喃葡萄糖苷[3β,12β,20(S)-trihy-droxy dammarane-3-O-β-D-glucopyranosyl(1-2)-β-D-glucopyranoside](HRG)即人参皂苷结构修饰物的体内抗肿瘤活性... 目的探讨新化合物3β,12β,20(S)-三羟基达玛-3-O-β-D-吡喃葡萄糖基(1-2)-β-D-吡喃葡萄糖苷[3β,12β,20(S)-trihy-droxy dammarane-3-O-β-D-glucopyranosyl(1-2)-β-D-glucopyranoside](HRG)即人参皂苷结构修饰物的体内抗肿瘤活性。方法建立肝癌H22鸡胚尿囊膜(CAM)移植瘤模型,观察药物对移植瘤生长、诱导血管生成数、生长抑制率等的影响;将移植瘤切片及HE染色进行光镜组织形态的观察和测定;运用免疫组织化学染色(S-P法)检测移植瘤微血管密度及血管内皮生长因子的表达情况。结果新化合物HRG 25、50、100μg.mL-13个剂量组对肝癌H22-CAM移植瘤生长均有抑制作用,其抑瘤率分别为27.73%、50.02%、64.21%;HRG可显著减少移植瘤诱导血管生成数,且光镜下观察发现各用药组移植瘤组织均存在不同程度坏死,坏死程度与移植瘤诱导血管生成数成反比例关系;HRG可降低移植瘤的微血管密度,并下调血管内皮生长因子的表达。结论 HRG具有体内抗肿瘤活性,能够显著抑制肝癌H22-CAM移植瘤的生长和其诱导的血管生成,其机制可能与降低移植瘤微血管密度和下调血管内皮生长因子表达有关。 展开更多
关键词 12β 20(s)-三羟基达玛-3-O-β-D-吡喃葡萄糖基(1-2)-β-D-吡喃葡萄糖苷 肝癌H22细胞 鸡胚尿囊膜 移植瘤 血管生成
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部